Pharmaceutical software company Veeva Systems has sued Microsoft in California federal court, alleging Microsoft's Viva ...
In a report released today, Craig Hettenbach from Morgan Stanley maintained a Sell rating on Veeva Systems (VEEV – Research Report), with a price target of $195.00. The company’s shares closed ...
Biopharmas use leading CTMS for improved trial efficiency and collaboration BARCELONA, Spain, Jan. 29, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 200 ...
CENTRAL TRUST Co decreased its position in shares of Veeva Systems Inc. (NYSE:VEEV – Free Report) by 11.0% during the 4th ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results